Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: VENETOCLAX, . Treffer: 15
2023
Moujalled, DM; Brown, FC; Chua, CC; Dengler, MA; Pomilio, G; Anstee, NS; Litalien, V; Thompson, E; Morley, T; MacRaild, S; Tiong, IS; Morris, R; Dun, K; Zordan, A; Shah, J; Banquet, S; Halilovic, E; Morris, E; Herold, MJ; Lessene, G; Adams, JM; Huang, DCS; Roberts, AW; Blombery, P; Wei, AH
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
Blood. 2023; 141(6):634-644
Doi: 10.1182/blood.2022016090
Web of Science
PubMed
FullText
FullText_MUG
Thomas, D; Wu, M; Nakauchi, Y; Zheng, M; Thompson-Peach, CAL; Lim, K; Landberg, N; Köhnke, T; Robinson, N; Kaur, S; Kutyna, M; Stafford, M; Hiwase, D; Reinisch, A; Peltz, G; Majeti, R
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
Cancer Discov. 2023; 13(2):496-515
Doi: 10.1158/2159-8290.CD-21-0218
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2022
Blombery, P; Lew, TE; Dengler, MA; Thompson, ER; Lin, VS; Chen, X; Nguyen, T; Panigrahi, A; Handunnetti, SM; Carney, DA; Westerman, DA; Tam, CS; Adams, JM; Wei, AH; Huang, DCS; Seymour, JF; Roberts, AW; Anderson, MA
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood. 2022; 139(8):1198-1207
Doi: 10.1182/blood.2021012775
Web of Science
PubMed
FullText
FullText_MUG
Prochazka, KT; Uhl, B
Bcl2 inhibitor venetoclax +/- Anti-CD20: what do deep remissions mean?
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-021-00778-2
Web of Science
FullText
FullText_MUG
Wirth, AK; Wange, L; Vosberg, S; Henrich, KO; Rausch, C; Özdemir, E; Zeller, CM; Richter, D; Feuchtinger, T; Kaller, M; Hermeking, H; Greif, PA; Senft, D; Jurinovic, V; Bahrami, E; Jayavelu, AK; Westermann, F; Mann, M; Enard, W; Herold, T; Jeremias, I
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.
Leukemia. 2022; 36(12):2863-2874
Doi: 10.1038/s41375-022-01726-7
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2021
Eisenwort, G; Sadovnik, I; Keller, A; Ivanov, D; Peter, B; Berger, D; Stefanzl, G; Bauer, K; Slavnitsch, K; Greiner, G; Gleixner, KV; Sperr, WR; Willmann, M; Sill, H; Bettelheim, P; Geissler, K; Deininger, M; Rülicke, T; Valent, P
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
Leukemia. 2021; 35(11):3176-3187
Doi: 10.1038/s41375-021-01227-z
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Odinius, TO; Buschhorn, L; Wagner, C; Hauch, RT; Dill, V; Dechant, M; Buck, MC; Shoumariyeh, K; Moog, P; Schwaab, J; Reiter, A; Brockow, K; Götze, K; Bassermann, F; Höckendorf, U; Branca, C; Jost, PJ; Jilg, S
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
J CANCER RES CLIN. 2021;
Doi: 10.1007/s00432-021-03827-9
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Scheipl, S; Barnard, M; Lohberger, B; Zettl, R; Brcic, I; Liegl-Atzwanger, B; Rinner, B; Meindl, C; Fröhlich, E
Drug combination screening as a translational approach toward an improved drug therapy for chordoma.
Cell Oncol (Dordr). 2021; 44(6):1231-1242
Doi: 10.1007/s13402-021-00632-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Staber, PB; Jurczak, W; Greil, R; Vucinic, V; Middeke, JM; Montillo, M; Munir, T; Neumeister, P; Schetelig, J; Stilgenbauer, S; Striebel, F; Dirnberger-Hertweck, M; Weirather, J; Brugger, W; Kelemen, P; Wendtner, CM; Woyach, JA
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leuk Lymphoma. 2021; 62(14):3440-3451
Doi: 10.1080/10428194.2021.1964020
Web of Science
PubMed
FullText
FullText_MUG
Thijssen, R; Diepstraten, ST; Moujalled, D; Chew, E; Flensburg, C; Shi, MX; Dengler, MA; Litalien, V; MacRaild, S; Chen, M; Anstee, NS; Reljić, B; Gabriel, SS; Djajawi, TM; Riffkin, CD; Aubrey, BJ; Chang, C; Tai, L; Xu, Z; Morley, T; Pomilio, G; Bruedigam, C; Kallies, A; Stroud, DA; Bajel, A; Kluck, RM; Lane, SW; Schoumacher, M; Banquet, S; Majewski, IJ; Strasser, A; Roberts, AW; Huang, DCS; Brown, FC; Kelly, GL; Wei, AH
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Blood. 2021; 137(20): 2721-2735.
Doi: 10.1182/blood.2020010167
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Dengler, MA; Teh, CE; Thijssen, R; Gangoda, L; Lan, P; Herold, MJ; Gray, DH; Kelly, GL; Roberts, AW; Adams, JM
Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
Oncogene. 2020; 39(9):2009-2023
Doi: 10.1038/s41388-019-1122-x
Web of Science
PubMed
FullText
FullText_MUG
Roca-Portoles, A; Rodriguez-Blanco, G; Sumpton, D; Cloix, C; Mullin, M; Mackay, GM; O'Neill, K; Lemgruber, L; Luo, X; Tait, SWG
Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition.
Cell Death Dis. 2020; 11(8): 616
Doi: 10.1038/s41419-020-02867-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Sill, H; Zebisch, A; Haase, D
Acute Myeloid Leukemia and Myelodysplastic Syndromes with TP53 Aberrations - A Distinct Stem Cell Disorder.
Clin Cancer Res. 2020; 26(20):5304-5309
Doi: 10.1158/1078-0432.CCR-20-2272
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Steiger, K; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
Eur J Haematol. 2019; 102(5):437-441
Doi: 10.1111/ejh.13218
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Jilg, S; Hauch, RT; Kauschinger, J; Buschhorn, L; Odinius, TO; Dill, V; Müller-Thomas, C; Herold, T; Prodinger, PM; Schmidt, B; Hempel, D; Bassermann, F; Peschel, C; Götze, KS; Höckendorf, U; Haferlach, T; Jost, PJ
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.
Exp Hematol Oncol. 2019; 8(10):9-9
Doi: 10.1186/s40164-019-0133-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG